Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Accumulated Expenses data on file, last reported at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 3.04% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (up 3.04% YoY), and the FY2025 full-year result was $23.4 million, up 9.21% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $19.8 million, down from $23.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.4 million in Q4 2025 and bottomed at $14.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $20.0 million (2023), against an average of $19.5 million.
• The widest annual swing landed in 2022, when Accumulated Expenses surged 54.72%; it then decreased 20.94% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $21.1 million in 2022, then declined by 5.16% to $20.0 million in 2023, then rose by 7.03% to $21.4 million in 2024, then increased by 9.21% to $23.4 million in 2025, then decreased by 15.53% to $19.8 million in 2026.
• The last three Accumulated Expenses figures came in at $19.8 million (Q1 2026), $23.4 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.

Peer Comparison